Status:
COMPLETED
Antibody Responses to Pneumococcal Vaccines Among HIV-Infected Adults.
Lead Sponsor:
French National Agency for Research on AIDS and Viral Hepatitis
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3...
Detailed Description
Streptococcus pneumoniae (SP) is the major cause of bacterial infection in HIV-infected patients. The 23-valent pneumococcal polysaccharide (PPV) is poorly immunogenic in patients with CD4 below 500 c...
Eligibility Criteria
Inclusion
- Adult patients with proven HIV-1 infection
- Naïve or antiretroviral experienced
- CD4 cell count between 200 and 500/mm3
- Plasma HIV RNA load lower than 4 log10 copies/mL
- Signed written informed consent
Exclusion
- Immunotherapy
- Immunization with the PPV within the past 5 years
- Splenectomy
- Use of intravenous immunoglobulin within the past 2 months
- Chemotherapy or radiation
- Any other vaccination within the past 2 months
- Severe renal failure
- End-stage liver disease
- Pregnancy
Key Trial Info
Start Date :
February 1 2003
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
212 Patients enrolled
Trial Details
Trial ID
NCT00148824
Start Date
February 1 2003
End Date
January 1 2006
Last Update
March 21 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.